1. Борджи К, Амбросиони Е, Ново С и др. от имени Рабочей группы исследования SMILE-4. Сравнение терапии зофеноприлом и рамиприлом в сочетании с ацетилсалициловой кислотой у пациентов с систолической дисфункцией левого желудочка после острого инфаркта миокарда: результаты европейского многоцентрового рандомизированного двойного слепого исследования в параллельных группах (SMILE4). Рос. кардиол. журн. 2012; 96 (4): 5–13.
2. Арутюнов Г.П., Розанов А.В. Некоторые аспекты совместного применения ацетилсалициловой кислоты и ингибиторов АПФ у больных в постинфарктном периоде. Клин. фармакология и терапия. 2000; 9 (4): 16–8.
3. Морозова Т.Е., Андрущишина Т.Б., Ошорова С.Д. Индивидуализированный выбор антигипертензивных лекарственных средств при метаболическом синдроме: влияние на адипокины, маркеры эндотелиальной дисфункции и системного воспаления. Лечащий врач. 2011; 2: 11–5.
4. Морозова Т.Е., Андрущишина Т.Б., Ошорова С.Д. Оптимизация фармакотерапии артериальной гипертнзии у больных метаболическим синдромом – возможности зофеноприла. Рос. кардиол. журн. 2011; 90 (4): 63–8.
5. Морозова Т.Е., Вартанова О.А. Возможности применения ИАПФ Престариума А в коррекции коронарного и миокардиального резервов у больного ишемической болезнью сердца: клинический разбор. Фарматека. 2011; 15: 82–6.
6. Шилов А.М., Осмия А.О., Еремина И.В., Черепанова Е.В. Нитраты в практике врача первичного звена. Трудный пациент. 2010; 11: 4–8.
7. ACC/AHA 2002 Guideline Update for the management of patients with chronic stable angina-summary article. A Report of the ACC/AHA Task Force on Practice Guidelines. Circulation 2003; 107: 149–58.
8. Al-Khadra A, Salem D, Rand W. Antiplatelet agents and survival: a cohort analysis from the studies of left ventricular Dysfunction (SOLVD) trial. J Am Coll Cardiol 1998; 31: 419–25.
9. Ambrosioni Е, Borghi С, Маgnani В. Early treatment of acute myocardial infarction with angiotensin-converting еnzymе inhibitiоn: safety considerations. SMILE pilot study working рarty. Аm J Cardiol 1991; 68 (14): 101D–110D.
10. Ambrosioni Е, Borghi С, Маgnani В. Survival of mуосardiаl infarction long-term eva1uation (SМILE) study: rationale, design, organization, and outcome definitions. Control Сlin Trials 1994; 15 (3): 201–10.
11. Ambrosioni E, Borghi C, Magnani B. The effect of the angiotensin-converting-enzyme inhibitor zofenopril on mortality and morbidity after anterior myocardial infarction. The Survival of Myocardial Infarction Long-Term Evaluation (SMILE) Study Investigators.N Engl J Med 1995; 332 (2): 80–5.
12. Borghi C, Ambrosioni E. Survival of Myocardial Infarction Long-term Evaluation-2 Working PartyDouble-blind comparison between zofenopril and lisinopril in patients with acute myocardial infarction: results of the Survival of Myocardial Infarction Long-term Evaluation-2 (SMILE-2) study. Am Heart J 2003; 1 45: 80–7.
13. Borghi C, Ambrosioni E. Effects of zofenopril on myocardial ischemia in post-myocardial infarction patients with preserved left ventricular function: The Survival of Myocardial Infarction Long-term Evaluation (SMILE)–ISCHEMIA study. Am Heart J 2007; 153 (3): 445.
14. Borghi C, Arrigo FG. Cicero and Ettore Ambrosioni Effects of early treatment with zofenopril in patients with myocardial infarction and metabolic syndrome: the SMILE Study Vasc Health Risk Manag 2008; 4 (3): 665–71.
15. Dagenais GR, Pogue J, Fox K et al. Angiotensin-convertingenzyme inhibitors in stable vascular disease without left ventricular systolic dysfunction or heart failure: a combined analysis of three trials. Lancet 2006; 368: 581–8.
16. Desideri G, Grassi D, Croce G et al. Different effects of angiotensin converting enzyme inhibitors on endothelin-1 and nitric oxide balance in human vascular endothelial cells: evidence of an oxidant-sensitive pathway. Med Inf 2008; 305087.
17. Diet F, Pratt RE, Berry GJ et al. Increased accumulation of tissue ACE in human atherosclerotic coronary artery disease. Circulation 1996; 94: 2756–67.
18. Dostal DE, Baker KM. The cardiac renin-angiotensin system: conceptual, or a regulator of cardiac function? Circ Res 1999; 85: 643–50.
19. Dzau V, Bernstein K, Celermaier D et al. The relevance of tissue ACE: manifestations in mechanistic and endpoint data. Am J Cardiol 2001; 88 (Suppl. L): 1–20.
20. Cleland JG. Is aspirin «the weakest link» in cardiovascular prophylaxis? The surprising lack of evidence supporting the use of aspirin for cardiovascular disease. Prog Cardiovasc Dis 2002; 44: 275–92.
21. Cushman DW, Wang FL, Fung WC et al. Differentiation of angiotensin converting enzyme (ACE) inhibitors by their selective inhibition of ACE in physiologically important target organs. Am J Hypertens 1989; 2: 294–307.
22. Fogari R, Mugellini A, Zoppi A et al. Losartan and perindopril effects on plasma plaasminogen activator inhibitor-1 and fibrinogen in hypertensive type 2 diabetic patients. Am J Hypertens 2002; 15: 316–20.
23. Grundy SM, Cleeman JI, Merz CN et al. Implications of recent clinical trials for the the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004; 110: 227–39.
24. Guazzi M, Pontone G, Piergiuseppe A. Aspirin vorsnes exercise performans and pulmonare gas exchange in patients with heart failure who are taking angiotensin-converting enzyme inhibitors. Am Heart J 1999; 138 (138): 254–60.
25. Isnard R, Baroin J-P, Drobinski G et al. Influence of aspirin on long-term prognosis of patients with ischemic left ventricular systolic dysfunction [abstr]. Circulation 1998; 98 (Suppl. I): 1–300.
26. Harjai KJ, Solis S, Prasad A et al. Use of aspirin in conjunction with angiotensin-converting enzyme inhibitors does not worsen long-term survival in heart failure. Int J Cardiol 2003; 88: 207–14.
27. Horowitz JD. Tolerance induction during therapy with long-acting nitrates: how intensive is the «Collateral demadge»? Cardiovasc. Drugs Ther 2004; 18 (1): 11–2.
28. Latini R, Santoro E, Masson S et al. Aspirin does not interact with ACE inhibitors when both are given early after acute myocardial infarction: results of the GISSI-3 Trial. Heart Dis 2000; 2 (3): 185–90.
29. Leor J, Reicher-Reiss H, Goldbourt U et al. Aspirin and mortality in patients treated with angiotenzin-converting enzyms inhibitors J Am Coll Cardiol 1999; 33: 1920–5.
30. Liu X, Engelman RM, Rousou GA et al. Attenuation of myocardial reperfusion injury by sulfhydryl-containing angiotensin converting enzyme inhibitors. Cardiovasc Drugs Ther 1992; 6 (4): 437–43.
31. Morozova TE, Andrushchishina TB, Oshorova SD, Latiypova ER. The influence of zofenopril and nebivolol on adypokines activity and markers of endothelial dysfunction in hypertensive patients with metabolic syndrome. J Hypertens 2012; 30 (Suppl. A): 30, 477.
32. Napoli C, Sica V, de Nigris F et al. Sulfhydryl angiotensin-converting enzyme inhibition induces sustained reduction of systemic oxidative stress and improves the nitric oxide pathway in patients with essential hypertension. Am Heart J 2004; 148 (1): e5.
33. Napoli C, Bruzzese G, Ignarro LJ et al. Long-term treatment with sulfhydryl angiotensin-converting enzyme inhibition reduces carotid intima-media thickening and improves the nitric oxide/oxidative stress pathways in newly diagnosed patients with mild to moderate primary hypertension. Am Heart J 2008; 156 (6): 1154. e1–8.
34. Nawarskas JJ, Townsend RR, Cirigliano MD, Spinler SA. Effect of aspirin on blood pressure in hypertensive patients taking enalapril or losartan. Am J Hypertens 1999; 12: 784–9.
35. Nawarskas JJ, Spinler SA. Update on the Interaction Between Aspirin and Angiotensin-Converting Enzyme Inhibitors. Pharmacotherapy 2000; 20 (6): 698–710.
36. Nguyen KN, Aursnes I, Kjekshus J. Interaction between enalapril and aspirin on mortality after acute myocardial infarction: subgroup analysis of the Cooperative New Scandinavian Enalapril Survival Study II (CONSENSUS II). Am J Cardiol 1997; 79: 115–9.
37. Olson KL. Combined aspirin/ACE inhibitor treatment for CHF.  Ann Pharmacother 2001; 35: 1653–8.
38. Pasini AF, Garbin U, Nava MC et al. Effect of sulfhydryl and non-sulfhydryl angiotensin-converting enzyme inhibitors on endothelial function in essential hypertensive patients. Am J Hypertens 2007; 20 (4): 443–50.
39. Scientific Committee of the PERTINENT Sub-Study. PERTINENT-Perindopril-Thrombosis, Inflammation, Endothelial Dysfunction and Neurohormonal Activation Trial: a sub-study of the EUROPA study. Cardiovasc Drugs Ther 2003; 17: 83–91.
40. Scribner AW, Loscalzo J, Napoli C. The effect of angiotensin-converting enzyme inhibition on endothelial function and oxidant stress. Eur J Pharmacol 2003; 482 (1–3): 95–9.
41. Shichiri M et al. Plasma endothelin levels in hypertension and chronic renal failure Hypertension 1990; 15: 493–6.
42. Springer TA. Traffic signals for lymphocyte recirculation and leukocyte emigration: The multistep paradigm. Cell 1994; 76: 301–14.
43. Stys T, Lawson WE, Smaldone GC et al. Does aspirin attenuate the beneficial effects of angiotensin-converting enzyme inhibition in heart failure? Arch Intern Med 2000; 160: 1409–13.
44. Takkouche B, Etminan M, Caamano F et al. Interaction between aspirin and ACE Inhibitors: resolving discrepancies using a metaanalysis. Drug Saf 2002; 25: 373–8.
45. Teo KK, Yusuf S, Pfeffer M et al. ACE Inhibitors Collaborative Group. Effects of long-term treatment with angiotensin-convertingenzyme inhibitors in the presence or absence of aspirin: a systematic review. Lancet 2002; 360: 1037–43.
46. The EUROPA investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 2003; 362; 782–8.
47. Van Gilst Wh, de Graeff PA, de Leeuw MJ et al. Converting enzyme inhibitors and the role of the sulfhydryl group in the potentiation of exo- and endogenous nitrovasodilators. J Cardiovasc Pharmacol 1991; 18 (3): 429–36.

Т.Е.Морозова, Е.Р.Латыйпова 

ГБОУ ВПО Первый Московский государственный медицинский университет им. И.М.Сеченова Минздрава РФ